Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid [7]

American Journal of Gastroenterology

Volumn 95, Issue 10, 2000, Pages 2990-2992

  Kurihara, Takeshi ^a   Niimi, Akiko ^a   Maeda, Atsushi ^a   Shigemoto, Mutsuo ^a   Yamashita, Katsuko ^a  

^a Tokyo Women s Medical University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; URSODEOXYCHOLIC ACID;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; LIVER BIOPSY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033792659     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02013-X     Document Type: Letter

References (10)

1. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
2. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis
3. Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis
4. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: A preliminary study
5. Effect of bezafibrate in the treatment of primary biliary cirrhosis
6. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse
7. Homozygous disruption of the murine mdr2 P glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
8. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
9. Fatty acids, eicosanoids, and hypolipemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator dependent-receptor ligand assay
10. 4 pathway to inflammation control